Anette L. E.
- Country
- Norway
- Department
- Department of Haematology
Research Overview
- Phase 3 Randomized Study of JNJ-79635322 Versus Teclistamab in Relapsed or Refractory Multiple Myeloma After Prior PI, IMiD, and Anti-CD38 Therapy
- Phase 3 Open-Label Study of Elranatamab vs. Elotuzumab, Pomalidomide, Dexamethasone, or Carfilzomib in Relapsed/Refractory Multiple Myeloma Post Anti-CD38 Therapy
- Phase 3 Randomized Study of Alnuctamab Versus Standard Regimens in Relapsed/Refractory Multiple Myeloma: Efficacy and Safety Evaluation
Data & Insights
Has run more than one trial at 66 of 222 partner sites.
Specializations
Multiple Myeloma Management
The investigator specializes in the treatment of multiple myeloma, with particular emphasis on developing therapeutic strategies for both newly diagnosed and relapsed/refractory cases.
- Newly Diagnosed Multiple Myeloma
- Relapsed/Refractory Multiple Myeloma
- Minimal Residual Disease Monitoring
Their work encompasses evaluation of novel therapeutic combinations and treatment optimization strategies.
Immunotherapy Approaches
The investigator focuses on innovative immunotherapeutic treatments in multiple myeloma, including evaluation of targeted antibody therapies and their combinations.
- Monoclonal Antibody Therapy
- Combination Immunotherapy
- Novel Agent Development
Their research explores the potential of new immunological approaches in treating multiple myeloma.
Treatment Optimization
The investigator conducts research on treatment sequencing and timing strategies, particularly in the context of disease progression and therapeutic resistance.
- Early Intervention Strategies
- Treatment Response Assessment
- Therapeutic Resistance Management
Their work aims to enhance treatment outcomes through optimal therapeutic timing and selection.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.